Frontline Ibrutinib Plus R-CHOP Misses Primary Endpoint in Phase III DLBCL Trial
Combining ibrutinib with standard R-CHOP did not improve event-free survival versus R-CHOP alone in the first-line setting for patients with diffuse large B-cell lymphoma.
Source: OncLive